IN8bio
Monday, February 26, 2024
Royale
Gene/Cell Therapy
IN8bio, a clinical-stage biopharmaceutical company, focuses on gamma-delta T cell product candidates for solid and liquid tumors. These T cells, naturally differentiating between healthy and diseased tissue, act as a bridge between innate and adaptive immunity, contributing to tumor killing, immune cell recruitment, and activation. IN8bio utilizes its DeltEx platform, employing allogeneic, autologous, iPSC, and genetically modified cell therapies. With expertise in gamma-delta T cell biology and proprietary genetic engineering, the company aims to identify and eradicate tumor cells.
Speakers
State
New York
Country
United States
Website
https://in8bio.com/
CEO/Top Company Official
William Ho
Lead Product in Development
INB-100 & INB-400
Development Phase of Primary Product
Phase II
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}